Arachidonic acid-mediated and serum-opsonized-zymosan-mediated inhibition of complement production by macrophages. Lack of requirement for endogenous arachidonic acid metabolites.
The ability of exogenous prostaglandins to inhibit complement production (CP) by monocytes and macrophages (M phi) suggests that endogenous arachidonic acid metabolites produced by these cells may also regulate their rate of CP. We assessed the regulatory influence of endogenous metabolites on CP by M phi utilizing exogenous arachidonic acid and serum-opsonized zymosan as stimulators of production of cyclooxygenase and lipoxygenase metabolites. The results of this study show that (i) the inhibition of CP caused by both agents is is independent of arachidonic acid metabolites, suggesting that endogenously produced metabolites do not influence CP, and (ii) arachidonic acid and serum-opsonized zymosan inhibit production by independent mechanisms.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology*; D002478:Cells, Cultured; D003175:Complement C2 / Q000096:biosynthesis; D003181:Complement C4 / Q000096:biosynthesis; D003165:Complement System Proteins / Q000096:biosynthesis*; D016861:Cyclooxygenase Inhibitors; D005260:Female; D006168:Guinea Pigs; D007700:Kinetics; D016859:Lipoxygenase Inhibitors; D008264:Macrophages / Q000187:drug effects / Q000276:immunology*; D008297:Male; D009113:Muramidase / Q000096:biosynthesis; D010587:Phagocytosis / Q000187:drug effects; D015054:Zymosan / Q000494:pharmacology*
D000893:Anti-Inflammatory Agents; D001095:Arachidonic Acids; D003175:Complement C2; D003181:Complement C4; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D016718:Arachidonic Acid; D003165:Complement System Proteins; D015054:Zymosan; D009113:Muramidase